HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Moghissi, K. Articles by Dixon, K. Search for Related Content PubMed PubMed Citation Articles by Moghissi, K. Articles by Dixon, K.

Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?

Section of Cardiothoracic Surgery, the Yorkshire Laser Centre, Goole, East Yorkshire, UK

CORRESPONDENCE: K. Moghissi, The Yorkshire Laser Centre, Goole and District Hospital, Woodland Avenue, Goole, East Yorkshire, DN14 6RX, UK. Fax: 44 01724290456. E-mail: kmoghissi@yorkshirelasercentre.org

Keywords: literature review, lung cancer, photodynamic therapy

Received: January 15, 2003
Accepted April 14, 2003

Abstract

This study addresses whether photodynamic therapy (PDT) is a valid therapeutic option in lung cancer treatment.

A total of 24 articles were reviewed in two categories: advanced (G1) and early (G2) disease. Details considered included the following: 1) number of patients in each series; 2) staging; 3) methodology; 4) mortality; 5) morbidity; 6) survival; 7) relief of symptoms; and 8) concomitant treatments. G1 (636 patients) had severe endobronchial obstructive cancer and PDT was primarily for symptom relief. G2 (517 patients) had early stage cancer and were treated with PDT for curative intent.

There was no procedure-related mortality in either group. G1 had a 5–28% incidence of skin sensitivity. Haemoptysis occurred in two series; one fatal, an incidence of 2.2%. Almost all patients had symptomatic relief. Patients with lower disease stage and better performance status had improved survival rates. G2 had a 8–28% incidence of sunburn. Three patients in one series (38 patients) had haemoptysis. Survival after 5 yrs in complete remission/response patients was 70%.

This review suggests that bronchoscopic photodynamic therapy has indications in selected lung cancer patients with early or advanced stage disease. However, in the absence of a formal comparative study, no claim can be made of its superiority over other endobronchial therapies.

This article has been cited by other articles:

				K. Moghissi, K. Dixon, J. A. C. Thorpe, M. Stringer, and C. Oxtoby Photodynamic therapy (PDT) in early central lung cancer: a treatment option for patients ineligible for surgical resection Thorax, May 1, 2007; 62(5): 391 - 395. [Abstract] [Full Text] [PDF]

				J-M. Vergnon, R. M. Huber, and K. Moghissi Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur. Respir. J., July 1, 2006; 28(1): 200 - 218. [Abstract] [Full Text] [PDF]

				K. Moghissi and K. Dixon Photodynamic therapy for synchronous occult bronchial cancer 17 years after pneumonectomy Interactive CardioVascular and Thoracic Surgery, August 1, 2005; 4(4): 327 - 328. [Abstract] [Full Text] [PDF]

				D. Moro-Sibilot and C. Brambilla Photodynamic therapy: where do we go from here? Eur. Respir. J., September 1, 2003; 22(3): 399 - 400. [Full Text] [PDF]